RVMDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as RVMDW
Revolution Medicines, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$182.15+4.19 (+2.35%)
Close on Oct 19, 2026
- Market cap
- $38.41B
- P/E (TTM)
- –
- Dividend yield
- –
Revolution Medicines, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| Collaboration Revenue | $35.38M | $29.39M | $42.98M | $50.04M | – | 100.0% | +20.4% |
| Collaboration Revenue, Related Party | – | – | $42.98M | $50.04M | $19.42M | – | – |
| Collaboration Revenue, Other | – | – | – | – | $745.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Revolution Medicines's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.